个人中心 - 老虎社区

miyakos

IP属地：未知

帖子 · 87帖子 · 87
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- miyakosmiyakos
  ·2021-09-14
  Latest
  FuelCell shares Popped 30% in morning trading
  FuelCell shares Popped 30% in morning trading on topping results forecasts. FuelCell reported a rar
  FuelCell shares Popped 30% in morning trading
  1,364 评论
  3
  分享
  举报
- miyakosmiyakos
  ·2021-09-13
  Latest
  非常抱歉，此主贴已删除
  1,175 1
  2
  分享
  举报
- miyakosmiyakos
  ·2021-09-09
  Latest
  This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029
  Doing business as usual will be more than enough to make this company a strong investment.
  This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029
  1,265 评论
  5
  分享
  举报
- miyakosmiyakos
  ·2021-09-08
  Latest
  Vanguard ETFs Lead as Flows Into U.S. Market Smash $600 Billion
  Previous record for full calendar year overtaken in late July. SPY assets top $400 billion as invest
  Vanguard ETFs Lead as Flows Into U.S. Market Smash $600 Billion
  1,003 4
  6
  分享
  举报
- miyakosmiyakos
  ·2021-09-07
  Latest
  Hong Kong stocks close higher after strong China exports surprise
  Hang Seng index ends up 0.73%. China Enterprises index HSCE rises 1.04%. HSI property sector down 1%
  Hong Kong stocks close higher after strong China exports surprise
  1,059 评论
  3
  分享
  举报
- miyakosmiyakos
  ·2021-09-06
  Latest
  This Could Be Novavax's Ace in the Hole
  Hint: It's not the company's COVID-19 vaccine. Key Points Novavax put its flu vaccine program on t
  This Could Be Novavax's Ace in the Hole
  690 评论
  3
  分享
  举报
- miyakosmiyakos
  ·2021-09-05
  Latest
  非常抱歉，此主贴已删除
  1,679 1
  7
  分享
  举报
- miyakosmiyakos
  ·2021-09-02
  Yeah
  非常抱歉，此主贴已删除
  1,882 评论
  4
  分享
  举报
- miyakosmiyakos
  ·2021-09-01
  Yes
  非常抱歉，此主贴已删除
  1,287 评论
  1
  分享
  举报
- miyakosmiyakos
  ·2021-08-31
  Latest
  非常抱歉，此主贴已删除
  899 评论
  2
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4088416347172780","uuid":"4088416347172780","gmtCreate":1625317032982,"gmtModify":1625317032982,"name":"miyakos","pinyin":"miyakos","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":5,"tweetSize":87,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":882081815,"gmtCreate":1631631128137,"gmtModify":1631890297396,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/882081815","repostId":"1185574136","repostType":4,"repost":{"id":"1185574136","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631630152,"share":"https://ttm.financial/m/news/1185574136?lang=&edition=full","pubTime":"2021-09-14 22:35","market":"us","language":"en","title":"FuelCell shares Popped 30% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1185574136","media":"Tiger Newspress","summary":"FuelCell shares Popped 30% in morning trading on topping results forecasts.\n\nFuelCell reported a rar","content":"<p>FuelCell shares Popped 30%&nbsp;in morning trading&nbsp;on&nbsp;topping results forecasts.</p>\n<p><img src=\"https://static.tigerbbs.com/d07b75f01716e7feb7fed0f8f5a9c300\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>FuelCell&nbsp;reported a rare narrower-than-expected fiscal third-quarter net loss, helped by higher gross margin, and revenue that rose above forecasts. The net loss narrowed to $12.8 million, or 4 cents a share, from $16.1 million, or 7 cents a share, in the same period a year ago. That beat the FactSet consensus for per-share losses of 5 cents, to snap a seven-quarter streak of wider-than-expected losses. Revenue rose 43.2% to $26.8 million from $18.7 million, above the FactSet consensus of $21.1 million, boosted by a $7.2 million increase in service agreements and license revenue. Gross margin improved to positive 4.1% from negative 16.7%. The stock has tumbled 49.7% year to date through Monday, while the S&amp;P 500 has gained 19.0%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FuelCell shares Popped 30% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFuelCell shares Popped 30% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-14 22:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FuelCell shares Popped 30%&nbsp;in morning trading&nbsp;on&nbsp;topping results forecasts.</p>\n<p><img src=\"https://static.tigerbbs.com/d07b75f01716e7feb7fed0f8f5a9c300\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>FuelCell&nbsp;reported a rare narrower-than-expected fiscal third-quarter net loss, helped by higher gross margin, and revenue that rose above forecasts. The net loss narrowed to $12.8 million, or 4 cents a share, from $16.1 million, or 7 cents a share, in the same period a year ago. That beat the FactSet consensus for per-share losses of 5 cents, to snap a seven-quarter streak of wider-than-expected losses. Revenue rose 43.2% to $26.8 million from $18.7 million, above the FactSet consensus of $21.1 million, boosted by a $7.2 million increase in service agreements and license revenue. Gross margin improved to positive 4.1% from negative 16.7%. The stock has tumbled 49.7% year to date through Monday, while the S&amp;P 500 has gained 19.0%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FCEL":"燃料电池能源"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185574136","content_text":"FuelCell shares Popped 30% in morning trading on topping results forecasts.\n\nFuelCell reported a rare narrower-than-expected fiscal third-quarter net loss, helped by higher gross margin, and revenue that rose above forecasts. The net loss narrowed to $12.8 million, or 4 cents a share, from $16.1 million, or 7 cents a share, in the same period a year ago. That beat the FactSet consensus for per-share losses of 5 cents, to snap a seven-quarter streak of wider-than-expected losses. Revenue rose 43.2% to $26.8 million from $18.7 million, above the FactSet consensus of $21.1 million, boosted by a $7.2 million increase in service agreements and license revenue. Gross margin improved to positive 4.1% from negative 16.7%. The stock has tumbled 49.7% year to date through Monday, while the S&P 500 has gained 19.0%.","news_type":1,"symbols_score_info":{"FCEL":0.9}},"isVote":1,"tweetType":1,"viewCount":1364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888750587,"gmtCreate":1631532248849,"gmtModify":1631890297413,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/888750587","repostId":"1133730816","repostType":4,"isVote":1,"tweetType":1,"viewCount":1175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883019705,"gmtCreate":1631188037807,"gmtModify":1631890297422,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883019705","repostId":"2166312201","repostType":4,"repost":{"id":"2166312201","kind":"highlight","pubTimestamp":1631187660,"share":"https://ttm.financial/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1,"symbols_score_info":{"ISRG":0.9}},"isVote":1,"tweetType":1,"viewCount":1265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889316628,"gmtCreate":1631109353464,"gmtModify":1631890297432,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/889316628","repostId":"1131499618","repostType":4,"repost":{"id":"1131499618","kind":"news","pubTimestamp":1631109033,"share":"https://ttm.financial/m/news/1131499618?lang=&edition=full","pubTime":"2021-09-08 21:50","market":"us","language":"en","title":"Vanguard ETFs Lead as Flows Into U.S. Market Smash $600 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1131499618","media":"Bloomberg","summary":"Previous record for full calendar year overtaken in late July.\nSPY assets top $400 billion as invest","content":"<ul>\n <li>Previous record for full calendar year overtaken in late July.</li>\n <li>SPY assets top $400 billion as investors seek broad exposure.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/171bc9156c18b449edf7d973c856165b\" tg-width=\"1000\" tg-height=\"562\" width=\"100%\" height=\"auto\">Six weeks after topping a record for yearly inflows, exchange-traded funds in the U.S. have added another $100 billion.</p>\n<p>Investors have now poured $605 billion into the $6.8 trillion industry in 2021, according to data compiled by Bloomberg. The previous record for a full calendar year was $497 billion in 2020, which wasovertaken in late July.</p>\n<p><img src=\"https://static.tigerbbs.com/ca32a20513525c0a100f7ce536aeb50b\" tg-width=\"800\" tg-height=\"292\" width=\"100%\" height=\"auto\">Judging by the flows, investors have been generally keen to ride the broad market rebound from the pandemic that saw benchmark American equity gauges notch dozens of all-time-highs this year.</p>\n<p>The biggest winner is currently the Vanguard S&amp;P 500 ETF (tickerVOO) -- with $37.2 billion in new cash -- while the second place is the Vanguard Total Stock Market ETF (VTI), with $28.7 billion.</p>\n<p>The world’s largest ETF, the SPDR S&amp;P 500 ETF Trust (SPY), is nowhere near top of the leader board with just $8 billion in money added this year. But thanks to that and the rallying S&amp;P 500 index, its assets surpassed $400 billion for the first time in August.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vanguard ETFs Lead as Flows Into U.S. Market Smash $600 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVanguard ETFs Lead as Flows Into U.S. Market Smash $600 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-09-08/vanguard-etfs-lead-as-flows-into-u-s-market-smash-600-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Previous record for full calendar year overtaken in late July.\nSPY assets top $400 billion as investors seek broad exposure.\n\nSix weeks after topping a record for yearly inflows, exchange-traded funds...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-09-08/vanguard-etfs-lead-as-flows-into-u-s-market-smash-600-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.bloomberg.com/news/articles/2021-09-08/vanguard-etfs-lead-as-flows-into-u-s-market-smash-600-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131499618","content_text":"Previous record for full calendar year overtaken in late July.\nSPY assets top $400 billion as investors seek broad exposure.\n\nSix weeks after topping a record for yearly inflows, exchange-traded funds in the U.S. have added another $100 billion.\nInvestors have now poured $605 billion into the $6.8 trillion industry in 2021, according to data compiled by Bloomberg. The previous record for a full calendar year was $497 billion in 2020, which wasovertaken in late July.\nJudging by the flows, investors have been generally keen to ride the broad market rebound from the pandemic that saw benchmark American equity gauges notch dozens of all-time-highs this year.\nThe biggest winner is currently the Vanguard S&P 500 ETF (tickerVOO) -- with $37.2 billion in new cash -- while the second place is the Vanguard Total Stock Market ETF (VTI), with $28.7 billion.\nThe world’s largest ETF, the SPDR S&P 500 ETF Trust (SPY), is nowhere near top of the leader board with just $8 billion in money added this year. But thanks to that and the rallying S&P 500 index, its assets surpassed $400 billion for the first time in August.","news_type":1,"symbols_score_info":{"VTCIF":0.9}},"isVote":1,"tweetType":1,"viewCount":1003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880987948,"gmtCreate":1631009921884,"gmtModify":1631890297446,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/880987948","repostId":"2165330144","repostType":4,"repost":{"id":"2165330144","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631005899,"share":"https://ttm.financial/m/news/2165330144?lang=&edition=full","pubTime":"2021-09-07 17:11","market":"sh","language":"en","title":"Hong Kong stocks close higher after strong China exports surprise","url":"https://stock-news.laohu8.com/highlight/detail?id=2165330144","media":"Reuters","summary":"Hang Seng index ends up 0.73%.\nChina Enterprises index HSCE rises 1.04%.\nHSI property sector down 1%","content":"<ul>\n <li>Hang Seng index ends up 0.73%.</li>\n <li>China Enterprises index HSCE rises 1.04%.</li>\n <li>HSI property sector down 1% as Evergrande slumps.</li>\n</ul>\n<p>SHANGHAI, Sept 7 (Reuters) - Hong Kong shares rose on Tuesday after data showed China's exports unexpectedly grew at a faster pace in August, helping to take some of the pressure off the world's second-biggest economy in the midst of an uneven recovery.</p>\n<p>Exports from China rose in August at a faster-than-expected rate of 25.6% from a year earlier, up from a 19.3% gain in July, pointing to some resilience in China's industrial sector.</p>\n<p>At the close of trade, the Hang Seng index was up 190.00 points or 0.73% at 26,353.63. The Hang Seng China Enterprises index rose 1.04% to 9,468.22.</p>\n<p>The sub-index of the Hang Seng tracking energy shares&nbsp;rose 1.3%, while the IT sector rose 2.05% and the financial sector ended 0.21% higher.</p>\n<p>The top gainer on the Hang Seng was Li Ning Co Ltd, which gained 7.27%, while the biggest loser was Country Garden Holdings Co Ltd, which fell 4.06%.</p>\n<p>The property sector fell 0.98% as investor concerns over highly indebted developer <a href=\"https://laohu8.com/S/EGRNF\">China Evergrande Group</a> continued to hit the company's shares and bonds.</p>\n<p>The three biggest H-shares percentage decliners were Evergrande Property Services Group Ltd, which fell 7.96%, China Evergrande Group, which fell 7.75% and China Feihe Ltd, down 4.32%.</p>\n<p>China's main Shanghai Composite index closed up 1.51% at 3,676.59 points, while the blue-chip CSI300 index ended up 1.2%.</p>\n<p>About 1.84 billion Hang Seng index shares were traded, roughly 85% of the market's 30-day moving average of 2.17 billion shares a day. The volume traded in the previous trading session was 1.91 billion.</p>\n<p>At close, China's A-shares were trading at a premium of 40.46% over Hong Kong-listed H-shares.</p>\n<p>(Reporting by Andrew Galbraith; Editing by Shounak Dasgupta)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong stocks close higher after strong China exports surprise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong stocks close higher after strong China exports surprise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-07 17:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Hang Seng index ends up 0.73%.</li>\n <li>China Enterprises index HSCE rises 1.04%.</li>\n <li>HSI property sector down 1% as Evergrande slumps.</li>\n</ul>\n<p>SHANGHAI, Sept 7 (Reuters) - Hong Kong shares rose on Tuesday after data showed China's exports unexpectedly grew at a faster pace in August, helping to take some of the pressure off the world's second-biggest economy in the midst of an uneven recovery.</p>\n<p>Exports from China rose in August at a faster-than-expected rate of 25.6% from a year earlier, up from a 19.3% gain in July, pointing to some resilience in China's industrial sector.</p>\n<p>At the close of trade, the Hang Seng index was up 190.00 points or 0.73% at 26,353.63. The Hang Seng China Enterprises index rose 1.04% to 9,468.22.</p>\n<p>The sub-index of the Hang Seng tracking energy shares&nbsp;rose 1.3%, while the IT sector rose 2.05% and the financial sector ended 0.21% higher.</p>\n<p>The top gainer on the Hang Seng was Li Ning Co Ltd, which gained 7.27%, while the biggest loser was Country Garden Holdings Co Ltd, which fell 4.06%.</p>\n<p>The property sector fell 0.98% as investor concerns over highly indebted developer <a href=\"https://laohu8.com/S/EGRNF\">China Evergrande Group</a> continued to hit the company's shares and bonds.</p>\n<p>The three biggest H-shares percentage decliners were Evergrande Property Services Group Ltd, which fell 7.96%, China Evergrande Group, which fell 7.75% and China Feihe Ltd, down 4.32%.</p>\n<p>China's main Shanghai Composite index closed up 1.51% at 3,676.59 points, while the blue-chip CSI300 index ended up 1.2%.</p>\n<p>About 1.84 billion Hang Seng index shares were traded, roughly 85% of the market's 30-day moving average of 2.17 billion shares a day. The volume traded in the previous trading session was 1.91 billion.</p>\n<p>At close, China's A-shares were trading at a premium of 40.46% over Hong Kong-listed H-shares.</p>\n<p>(Reporting by Andrew Galbraith; Editing by Shounak Dasgupta)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HSI":"恒生指数"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2165330144","content_text":"Hang Seng index ends up 0.73%.\nChina Enterprises index HSCE rises 1.04%.\nHSI property sector down 1% as Evergrande slumps.\n\nSHANGHAI, Sept 7 (Reuters) - Hong Kong shares rose on Tuesday after data showed China's exports unexpectedly grew at a faster pace in August, helping to take some of the pressure off the world's second-biggest economy in the midst of an uneven recovery.\nExports from China rose in August at a faster-than-expected rate of 25.6% from a year earlier, up from a 19.3% gain in July, pointing to some resilience in China's industrial sector.\nAt the close of trade, the Hang Seng index was up 190.00 points or 0.73% at 26,353.63. The Hang Seng China Enterprises index rose 1.04% to 9,468.22.\nThe sub-index of the Hang Seng tracking energy shares rose 1.3%, while the IT sector rose 2.05% and the financial sector ended 0.21% higher.\nThe top gainer on the Hang Seng was Li Ning Co Ltd, which gained 7.27%, while the biggest loser was Country Garden Holdings Co Ltd, which fell 4.06%.\nThe property sector fell 0.98% as investor concerns over highly indebted developer China Evergrande Group continued to hit the company's shares and bonds.\nThe three biggest H-shares percentage decliners were Evergrande Property Services Group Ltd, which fell 7.96%, China Evergrande Group, which fell 7.75% and China Feihe Ltd, down 4.32%.\nChina's main Shanghai Composite index closed up 1.51% at 3,676.59 points, while the blue-chip CSI300 index ended up 1.2%.\nAbout 1.84 billion Hang Seng index shares were traded, roughly 85% of the market's 30-day moving average of 2.17 billion shares a day. The volume traded in the previous trading session was 1.91 billion.\nAt close, China's A-shares were trading at a premium of 40.46% over Hong Kong-listed H-shares.\n(Reporting by Andrew Galbraith; Editing by Shounak Dasgupta)","news_type":1,"symbols_score_info":{"HSI":0.9}},"isVote":1,"tweetType":1,"viewCount":1059,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":817838648,"gmtCreate":1630929051884,"gmtModify":1631890297459,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/817838648","repostId":"1121589231","repostType":4,"repost":{"id":"1121589231","kind":"news","pubTimestamp":1630927585,"share":"https://ttm.financial/m/news/1121589231?lang=&edition=full","pubTime":"2021-09-06 19:26","market":"us","language":"en","title":"This Could Be Novavax's Ace in the Hole","url":"https://stock-news.laohu8.com/highlight/detail?id=1121589231","media":"Motley Fool","summary":"Hint: It's not the company's COVID-19 vaccine.\n\nKey Points\n\nNovavax put its flu vaccine program on t","content":"<blockquote>\n <b>Hint: It's not the company's COVID-19 vaccine.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Novavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.</li>\n <li>The company has already reported positive results from a late-stage study of its experimental NanoFlu flu vaccine.</li>\n <li>Novavax is moving forward with testing a COVID-19/flu combo that could potentially set the company apart from other vaccine makers.</li>\n</ul>\n<p><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> </b>has its skeptics. Some point to the company's history of failure. Its respiratory syncytial virus (RSV) vaccine candidate ResVax experienced two clinical setbacks, and it haspushed back its anticipated timelinefor filing for Emergency Use Authorizations (EUAs) of its COVID-19 vaccine candidate NVX-CoV2373 three times.</p>\n<p>However, the future for this biotech stock could be brighter than many critics think. Novavax should file for EUA in the U.K. for NVX-CoV2373 within weeks, followed quickly by filings in the European Union and other countries.</p>\n<p>Its COVID-19 vaccine, while somewhat late to the party, could still be a commercial success for Novavax. But there's also another candidate in the company's pipeline that just might be its ace in the hole.</p>\n<p><b>A hot candidate on the back burner</b></p>\n<p>With all of the hubbub over NVX-CoV2373, it's easy to forget that it wasn't all that long ago that investors were excited about another experimental vaccine developed by Novavax. The company had high hopes for flu vaccine candidate NanoFlu after reporting encouraging results in early 2018 from a phase 1/2 study.</p>\n<p>Novavax advanced NanoFlu into phase 2 testing in older adults in September 2018. It reported more good news from that clinical trial in January 2019.</p>\n<p>That set the stage for NanoFlu's phase 3 study -- a head-to-head comparison with<b>Sanofi</b>'s&nbsp;approved flu vaccine FluZone Quadrivalent. The study began in October 2019. The following March, Novavax announced positive results, with NanoFlu clearly beating FluZone in the study's primary and secondary endpoints.</p>\n<p>The company seemed to be set to move quickly to file for approval of NanoFlu. However, its flu vaccine program was pushed to the back burner with Novavax moving forward with its COVID-19 vaccine development.</p>\n<p><b>A compelling combo</b></p>\n<p>It made sense that Novavax chose to focus on its COVID-19 program. The opportunity was too great to ignore, and Novavax's resources could only be spread out so far. And with the U.S. government throwing $1.6 billion the company's way to develop NVX-CoV2373, a shift in priorities was a no-brainer.</p>\n<p>However, Novavax certainly hasn't forgotten about NanoFlu. The company thinks that a combination COVID-19/flu vaccine featuring NVX-CoV2373 and NanoFlu could be a winner.</p>\n<p>Novavax has already announced promising preclinical data evaluating a NanoFlu/NVX-CoV2373 combination vaccine. It plans to initiate a phase 1 study in Australia later this year to evaluate the experimental combo.</p>\n<p>NanoFlu truly could be the key to Novavax setting itself apart from other COVID-19 vaccine makers.<b>Pfizer</b>&nbsp;and<b>BioNTech</b>&nbsp;are working on a flu vaccine candidate, but it hasn't advanced into clinical testing yet.<b>Moderna</b>only recently began early-stage clinical studies of its experimental flu vaccine.</p>\n<p>Meanwhile, Novavax has already demonstrated NanoFlu's safety and efficacy. It's also already moving ahead with clinical testing of a COVID-19/flu combo vaccine, something that rivals haven't done yet. Should annual boosters for COVID-19 be needed in the future, a combo COVID-19/flu vaccine could provide a compelling value proposition. Novavax appears to be the leader on this front.</p>\n<p><b>A good bet?</b></p>\n<p>I understand why some might be skeptical about Novavax considering the company's past track record. However, the company is in a better position than ever to succeed. Novavax has already reported positive results for NVX-CoV2373 from late-stage studies in the U.K. and the U.S. The primary hurdle now is to complete the regulatory filings for the vaccine.</p>\n<p>Assuming Novavax wins EUAs, it should be set to make a boatload of money. The company recently signed a deal with the European Union to supply 100 million doses initially and up to 100 million additional doses of NVX-CoV2373. Novavax could soon have ample financial resources to fund its COVID-19/flu combo vaccine program.</p>\n<p>It's not surprising at all to me that analysts are bullish about thevaccine stock. With the attractive prospects for NVX-CoV2373 and NanoFlu as its ace in the hole, Novavax appears to be a pretty good bet.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Novavax's Ace in the Hole</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Novavax's Ace in the Hole\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-06 19:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hint: It's not the company's COVID-19 vaccine.\n\nKey Points\n\nNovavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.\nThe company has already reported ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121589231","content_text":"Hint: It's not the company's COVID-19 vaccine.\n\nKey Points\n\nNovavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.\nThe company has already reported positive results from a late-stage study of its experimental NanoFlu flu vaccine.\nNovavax is moving forward with testing a COVID-19/flu combo that could potentially set the company apart from other vaccine makers.\n\nNovavax has its skeptics. Some point to the company's history of failure. Its respiratory syncytial virus (RSV) vaccine candidate ResVax experienced two clinical setbacks, and it haspushed back its anticipated timelinefor filing for Emergency Use Authorizations (EUAs) of its COVID-19 vaccine candidate NVX-CoV2373 three times.\nHowever, the future for this biotech stock could be brighter than many critics think. Novavax should file for EUA in the U.K. for NVX-CoV2373 within weeks, followed quickly by filings in the European Union and other countries.\nIts COVID-19 vaccine, while somewhat late to the party, could still be a commercial success for Novavax. But there's also another candidate in the company's pipeline that just might be its ace in the hole.\nA hot candidate on the back burner\nWith all of the hubbub over NVX-CoV2373, it's easy to forget that it wasn't all that long ago that investors were excited about another experimental vaccine developed by Novavax. The company had high hopes for flu vaccine candidate NanoFlu after reporting encouraging results in early 2018 from a phase 1/2 study.\nNovavax advanced NanoFlu into phase 2 testing in older adults in September 2018. It reported more good news from that clinical trial in January 2019.\nThat set the stage for NanoFlu's phase 3 study -- a head-to-head comparison withSanofi's approved flu vaccine FluZone Quadrivalent. The study began in October 2019. The following March, Novavax announced positive results, with NanoFlu clearly beating FluZone in the study's primary and secondary endpoints.\nThe company seemed to be set to move quickly to file for approval of NanoFlu. However, its flu vaccine program was pushed to the back burner with Novavax moving forward with its COVID-19 vaccine development.\nA compelling combo\nIt made sense that Novavax chose to focus on its COVID-19 program. The opportunity was too great to ignore, and Novavax's resources could only be spread out so far. And with the U.S. government throwing $1.6 billion the company's way to develop NVX-CoV2373, a shift in priorities was a no-brainer.\nHowever, Novavax certainly hasn't forgotten about NanoFlu. The company thinks that a combination COVID-19/flu vaccine featuring NVX-CoV2373 and NanoFlu could be a winner.\nNovavax has already announced promising preclinical data evaluating a NanoFlu/NVX-CoV2373 combination vaccine. It plans to initiate a phase 1 study in Australia later this year to evaluate the experimental combo.\nNanoFlu truly could be the key to Novavax setting itself apart from other COVID-19 vaccine makers.Pfizer andBioNTech are working on a flu vaccine candidate, but it hasn't advanced into clinical testing yet.Modernaonly recently began early-stage clinical studies of its experimental flu vaccine.\nMeanwhile, Novavax has already demonstrated NanoFlu's safety and efficacy. It's also already moving ahead with clinical testing of a COVID-19/flu combo vaccine, something that rivals haven't done yet. Should annual boosters for COVID-19 be needed in the future, a combo COVID-19/flu vaccine could provide a compelling value proposition. Novavax appears to be the leader on this front.\nA good bet?\nI understand why some might be skeptical about Novavax considering the company's past track record. However, the company is in a better position than ever to succeed. Novavax has already reported positive results for NVX-CoV2373 from late-stage studies in the U.K. and the U.S. The primary hurdle now is to complete the regulatory filings for the vaccine.\nAssuming Novavax wins EUAs, it should be set to make a boatload of money. The company recently signed a deal with the European Union to supply 100 million doses initially and up to 100 million additional doses of NVX-CoV2373. Novavax could soon have ample financial resources to fund its COVID-19/flu combo vaccine program.\nIt's not surprising at all to me that analysts are bullish about thevaccine stock. With the attractive prospects for NVX-CoV2373 and NanoFlu as its ace in the hole, Novavax appears to be a pretty good bet.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":690,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814533960,"gmtCreate":1630840174950,"gmtModify":1631890297470,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/814533960","repostId":"2164803577","repostType":4,"isVote":1,"tweetType":1,"viewCount":1679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812568610,"gmtCreate":1630595120830,"gmtModify":1631890297482,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812568610","repostId":"2164821842","repostType":4,"isVote":1,"tweetType":1,"viewCount":1882,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816689882,"gmtCreate":1630495932646,"gmtModify":1631890297494,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/816689882","repostId":"2164894947","repostType":4,"isVote":1,"tweetType":1,"viewCount":1287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818206299,"gmtCreate":1630409504711,"gmtModify":1631890297508,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818206299","repostId":"2163859671","repostType":4,"isVote":1,"tweetType":1,"viewCount":899,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}